| http://www.w3.org/ns/prov#value | - ically ill patientsUS2007003680610 Jun 200415 Feb 2007Eli Lilly And Companyhave an increased half-life, decreased immunogenicity, and reduce effector activity; diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptyingUS2007012861926 May 20067 Ju
|
